Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 18/20 | 0.68 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.63 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.63 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.63 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1054612 | 0.94 | FYN (0.78) | FYNNTRK1NTRK3NTRK2PIK3CG | |
| SCHEMBL2946495 | 0.91 | FYN (0.64) | FYNNTRK1NTRK3NTRK2PIK3CG | |
| SCHEMBL2949854 | 0.88 | FYN (0.68) | FYNNTRK1NTRK3NTRK2 | |
| SCHEMBL23683386 | 0.88 | FYN (0.61) | FYNNTRK1NTRK3NTRK2PIK3CG | |
| SCHEMBL24828752 | 0.87 | FYN (0.61) | FYNNTRK1NTRK3NTRK2PIK3CG | |
| SCHEMBL1082260 | 0.86 | FYN (0.64) | FYNNTRK1NTRK3NTRK2PIK3CG | |
| SCHEMBL2943263 | 0.86 | NTRK1 (0.66) | FYNNTRK1NTRK3NTRK2 | |
| SCHEMBL23683338 | 0.85 | FYN (0.76) | FYNNTRK1NTRK3NTRK2PIK3CG | |
| SCHEMBL3021153 | 0.84 | NTRK1 (0.69) | FYNNTRK1NTRK3NTRK2 | |
| SCHEMBL23683388 | 0.84 | FYN (0.68) | FYNPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | BIOGEN IDEC MA INC. (US) | 2011-01-27 | — | — | US | claimed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| WO-2023192586-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-11542251-B2 | IRAK degraders and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| WO-2022125790-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| WO-2022087216-A1 | DOUBLE DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20210230144-A1 | IRAK DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-29 | — | — | US | disclosed |
| WO-2021011868-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | BIOGEN IDEC MA INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | FYN 996/4885NTRK1 1208/4885NTRK3 483/4885 |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | FYN 996/4885NTRK1 1208/4885NTRK3 483/4885 |
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | IRAK1, IRAK2, IRAK3 | FYN 666/4885NTRK1 750/4885NTRK3 896/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | FYN 996/4885NTRK1 1208/4885NTRK3 483/4885 |
| US-11542251-B2 | IRAK degraders and uses thereof | IRAK2, IRAK1, IRAK4 | FYN 1032/4885NTRK1 291/4885NTRK3 215/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | FYN 996/4885NTRK1 1208/4885NTRK3 483/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | FYN 996/4885NTRK1 1208/4885NTRK3 483/4885 |
| US-20210230144-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK1, IRAK4 | FYN 1032/4885NTRK1 291/4885NTRK3 215/4885 |
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | FYN 996/4885NTRK1 1208/4885NTRK3 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.